Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice TargetHot
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.